Organ Transplant Immunosuppressant Drugs Market Size

Organ Transplant Immunosuppressant Drugs Market Analysis

The organ transplant immunosuppressant drugs market is expected to register a CAGR of 3.5% during the forecast period.

COVID-19 significantly impacted the organ transplant immunosuppressant drugs market in the initial phases since many surgeries associated with organ transplantation got delayed along with the shutdown and primary care centers. Due to the delay, there was an enormous increase in the number of transplant candidates on the waiting list, which made the procedure more complicated. However, since the restrictions were eased, the industry has been reviving strongly. Over the previous two years, the market recovery has been driven by an upsurge in increased organ transplantations and new immunosuppressant product launches.

The organ transplant immunosuppressant drugs market is likely to grow over the forecast period because of the rising incidence of chronic diseases and technological advancements in organ transplantation, as these factors can increase the availability of the product in the market, which is anticipated to have a positive impact on the market. For instance, as per the HRSA 2022 update, more than 40,000 transplants were performed in the United States in 2021. As per the same source, there are 105,842 people, including men, women, and children, on the national transplant waiting list. Additionally, government collaborations, the launch of organ transplant centers, and transplantation awareness programs conducted globally are likely to increase market growth as these can expand product availability and improve competition. For instance, in September 2022, an organ transplant center was established in the Middle East, Africa, in Cairo, in cooperation with international companies. This organ transplant center includes an automated database for transplants, patients, and donors. Hence due to such initiatives, high demand for organ transplantation is likely to adopt immunosuppressant drugs as there is an increased chance of immunity reactions when transplantation has occurred. Moreover, in September 2022, the central government of India officially accredited Karnataka's State Organ Tissue Transplant Organisation (SOTTO) to encourage organ donations in the state. It sanctioned a budget of INR 84 lakh (USD 101 thousand) for the program. As a result, the increased investment in the programs associated with organ donation is likely to drive market growth. Patients with financial issues can also have organ transplantation, boosting the growth of the organ transplant immunosuppressant drugs market.

Furthermore, as per the article published in Frontiers in 2021, solid organ transplantation is the treatment of choice for many patients with end-stage organ dysfunction. As per the analysis, the study demonstrated the effectiveness of Tregs in solid organ transplantation trials by examining their effects on chronic rejection, acute rejection, graft versus host disease, and other associated diseases. Such research conducted in organ transplantation is likely to boost market growth. A heart transplantation surgery is also chosen for people with heart problems who have not progressed sufficiently with drugs or previous operations. According to the 2022 update from Mayo Clinic, survival rates continue to improve despite an increase in older and higher-risk heart transplant recipients. Adults worldwide have a one-year survival rate of nearly 90% and a five-year survival rate of roughly 80%. Additionally, the high prevalence of cystic fibrosis is a major fuelling factor for market growth since a patient with advanced lung diseases along with cystic fibrosis is likely to undergo a lung transplant to improve their quality of life. For instance, according to the CFF 2022 update, there are nearly 40,000 people in the United States with cystic fibrosis. As a result, considering the opportunities for transplantation to improve disease conditions, the market is expected to rise rapidly throughout the forecast period.

Hence, as per the factors mentioned above, the organ transplant immunosuppressant drugs market is anticipated to witness growth over the forecast period. However, the high cost of transplantation and less availability of organs restrain the market growth.